Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: Prognostic factors

Bone Marrow Transplantation

Volumn 25, Issue 8, 2000, Pages 885-894

  Brockstein, B E ^a   Smiley, C ^b   Al Sadir, J ^b   Williams, S F ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

Breast cancer; Cardiac toxicity; Ejection fraction; Lymphoma; Pulmonary toxicity; Stem cell transplant

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; THIOTEPA;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; FEMALE; HEART EJECTION FRACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

EID: 0034110517     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702234     Document Type: Article

References (45)

1. Brockstein BE, Williams SF. High-dose chemotherapy with autologous stem cell rescue For breast cancer: yesterday, today and tomorrow. Stem Cells 1996; 14: 79-89.
2. Dillman RO, Barth NM, Nayak SK et al. High-dose chemotherapy with autologous stem cell rescue in breast cancer. Breast Cancer Res Treat 1996; 37: 277-289.
3. Vandenberghe EA, Goldstone AH. Autologous stem cell transplants in lymphomas. Ann Med 1996; 28: 137-144.
4. Stasi R, Venditti A, Del Poeta G et al. High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. Leukemia Res 1996; 20: 535-549.
5. Droz JP, Culine S, Biron P et al. High-dose chemotherapy in germ-cell tumors. Ann Oncol 1996; 7: 997-1003.
6. Santos SW, Sensenbrenner LL, Bruke PJ et al. The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc 1972; 4: 559-564.
7. Goldberg MA, Antin JH, Guinan EC et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114-1118.
8. Braverman AC, Antin JH, Plappert MT et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-1223.
9. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
10. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
11. Bu'Lock FA, Mott MG, Oakhill A et al. Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child 1996; 75: 416-422.
12. Bristow MR, Thompson PD, Martin RP et al. Early anthracycline cardiotoxicity. Am J Med 1978; 65: 823-832.
13. Porembka DT, Lowder JN, Orlowski JP et al. Etiology and management of doxorubicin cardiotoxicity. Crit Care Med 1989; 17: 569-572.
14. Quezado ZM, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe reversible cardiac dysfunction. Ann Intern Med 1993; 118: 31-36.
15. Kandylis K, Vassilomanolakis M, Tsoussis S et al. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989; 24: 395-396.
16. Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987; 71: 733-736.
17. Martin M, Diaz-Rubio E, Furio V et al. Lethal cardiac toxicity after cisplatin and 5-fluorouracil chemotherapy. Am J Clin Oncol 1989; 12: 229-234.
18. Rowinsky EK, Eisenhauer EA, Chaudhry V et al. Clinical toxicities encountered with paclitaxel (taxol). Semin Oncol 1993; 20 (Suppl. 3): 1-15.
19. Wood AJ. Paclitaxel (taxol). New Engl J Med 1995; 332: 1004-1014.
20. Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer 1975; 36: 1979-1982.
21. Sivanesaratnam V. Mitomycin-C cardiotoxicity. Med J Aust 1989; 151: 300.
22. Schultz-Hector S. Radiation-induced heart disease: review of experimental data on dose response and pathogenesis. Int J Radiat Biol 1992; 61: 149-160.
23. Benoff LJ, Schweitzer P. Radiation therapy-induced cardiac injury. Am Heart J 1995; 129: 1193-1196.
24. Stewart JW, Fajardo LF, Gillette SM et al. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995; 31: 1205-1211.
25. Lopez-Jimenez J, Cervero C, Munoz A et al. Cardiovascular toxicities related to the infusion of cryopreserved grafts: results of a controlled study. Bone Marrow Transpl 1994; 13: 789-793.
26. Yellowlees P, Greenfield C, McIntyre N. Dimethylsulphoxide-induced toxicity. Lancet 1980; 8202: 1004-1006.
27. Hertenstein B, Stefanic M, Schmeiser T et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994; 12: 998-1004.
28. Bearman SI, Petersen FB, Schor RA et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 1990; 5: 173-177.
29. Durant JR, Norgard MJ, Murad TM et al. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med 1979; 90: 191-194.
30. Blum RH, Carter SK, Agre K. A clinical review of bleomycin - a new antineoplastic agent. Cancer 1973; 31: 903-914.
31. Krowka MJ, Rosenow EC, Hoagland HC. Pulmonary complications of bone marrow transplantation. Chest 1985; 87: 237-246.
32. Chan CK, Hyland RH, Hutcheon MA. Pulmonary complications following bone marrow transplantation. Clin Chest Med 1990; 11: 323-332.
33. Twohig K, Matthay R. Pulmonary effects of cytotoxic drugs other than bleomycin. Clin Chest Med 1990; 11: 31-54.
34. Todd NW, Peters WP, Ost AH et al. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Resp Dis 1993; 147: 1264-1270.
35. Przepiorka D, Dimopoulos M, Smith T et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Ann Hematol 1994; 68: 183-188.
36. Carlson K, Backlund L, Smedmyr B et al. Pulmonary function and complications subsequent to autologous bone marrow transplantation. Bone Marrow Transplant 1994; 14: 805-811.
37. Quakeck K. The lung as a critical organ in marrow transplantation. Bone Marrow Transplant 1994; 14 (Suppl. 4): S19-S28.
38. Hartsell WF, Czyzewski EA, Ghalie R et al. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide. Int J Radiat Oncol Biol Phys 1995; 32: 69-73.
39. Nichols DG, Walker LK, Wingard JR et al. Predictors of acute respiratory failure after bone marrow transplantation in children. Crit Care Med 1994; 22: 1485-1491.
40. Jochelson M, Tarbell NJ, Freedman AS et al. Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 1990; 6: 329-331.
41. Behar S, Graff E, Reicher-Reiss H et al. Low total cholesterol is associated with high total mortality in patients with coronary heart disease. Eur Heart J 1997; 18: 52-59.
42. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14: 2923-2932.
43. Fiorenza AM, Branchi A, Cardena A et al. Serum cholesterol levels in patients with cancer. Relationship with nutritional status. Int J Clin Lab Res 1996; 26: 37-42.
44. Hosmer DW Jr, Lemeshow, S. Applied Logistic Regression. John Wiley: New York, 1989.
45. Lawless JF, Singhal K. ISMOD: an all-subsets regression program for generalized linear models. I. Statistical and computational background. Comp Meth Prog Biomed 1987; 24: 117-124.